Once- vs Twice-Daily Enoxaparin for Bleeding Outcomes

In propensity analysis, patients on enoxaparin once daily had fewer bleeds, fewer deaths at 15, 30 days
In propensity analysis, patients on enoxaparin once daily had fewer bleeds, fewer deaths at 15, 30 days

HealthDay News — Once-daily enoxaparin is associated with fewer major bleeds than enoxaparin twice daily in patients with acute venous thromboembolism (VTE), according to a study published online in the Journal of Thrombosis and Haemostasis.

Javier Trujillo-Santos, MD, PhD, from the Hospital General Universitario Santa Lucía in Murcia, Spain, and colleagues assessed data from the RIETE registry for 4,730 patients receiving enoxaparin: 3,786 and 944 received enoxaparin twice and once daily, respectively. 

Related Articles

The researchers found that, compared with those receiving enoxaparin twice daily, once-daily enoxaparin correlated with a trend toward more VTE recurrences (odds ratio [OR], 1.79; 95% confidence interval [CI], 0.55 to 5.88), fewer major bleeds (OR, 0.42; 95% CI, 0.17 to 1.08), and fewer deaths (OR, 0.32; 95% CI, 0.13 to 0.78) during the first 15 days. Patients on enoxaparin once daily had more VTE recurrences (OR, 2.5; 95 percent CI, 1.03 to 5.88), fewer major bleeds (OR, 0.40; 95% CI, 0.17 to 0.94), and fewer deaths (OR, 0.58; 95% CI, 0.33 to 1.00) at day 30. On propensity analysis, patients on enoxaparin once daily had fewer bleeds at 15 and 30 days (hazard ratios, 0.30 [95% CI, 0.10 to 0.88] and 0.16 [95% CI, 0.04 to 0.68]) and fewer deaths at 15 and 30 days (hazard ratios, 0.37 [95% CI, 0.14 to 0.99] and 0.19 [95% CI, 0.07 to 0.54]).

"Enoxaparin prescribed once daily results in fewer major bleeds than enoxaparin twice daily," the authors write.

The RIETE registry was supported by Sanofi Spain and Bayer Pharma AG.

Full Text (subscription or payment may be required)